FLURADOG 30

EXTERNAL ANTIPARASITIC

Flavored Tablets

REG. SAN: RIP-02-FAR-01196

Formula:

Each tablet contains:

1
Fluralaner — 50 mg
Excipients q.s. to — 1 tablet
Biotin
Vitamin B12

2
Fluralaner — 100 mg
Excipients q.s. to — 1 tablet
Biotin
Vitamin B12

3
Fluralaner — 200 mg
Excipients q.s. to — 1 tablet
Biotin
Vitamin B12

4
Fluralaner — 400 mg
Excipients q.s. to — 1 tablet
Biotin
Vitamin B12

INDICATIONS:

FLURADOG 30 is an external antiparasitic indicated for the control and prevention of flea, tick, and mite infestations in dogs. Its action provides protection for approximately 30 days. It is effective in the treatment of canine demodicosis and scabies. It can be safely administered to pregnant and lactating females.

ROUTE OF ADMINISTRATION: Oral

SPECIES AND DOSAGE:

DOSAGE

50 mg Tablet
DOSAGE
Reference dose: 11.11 mg to 25 mg/kg
Species: Dogs
Weight: 2–4.5 kg
Practical Dose: 1 Tablet

100 mg Tablet
DOSAGE
Reference dose: 10–22.22 mg/kg
Species: Dogs
Weight: >4.5–10 kg
Practical Dose: 1 Tablet

200 mg Tablet
DOSAGE
Reference dose: 10–20 mg/kg
Species: Dogs
Weight: >10–20 kg
Practical Dose: 1 Tablet

400 mg Tablet
DOSAGE
Reference dose: 10–20 mg/kg
Species: Dogs
Weight: >20–40 kg
Practical Dose: 1 tablet

PHARMACOKINETICS:

After oral administration in dogs, the elimination half-life is approximately 9–16 days. The bioavailability of fluralaner following oral or topical administration is approximately 25%. Administering the tablet with food increases bioavailability by approximately 2–2.5 times. Due to its high degree of plasma protein binding, it is assumed that the primary route of elimination is hepatic.

MECHANISM OF ACTION:

Fluralaner inhibits gamma-aminobutyric acid (GABA) and glutamate-gated chloride channels, with significant selectivity for insect neurons over mammalian neurons. This inhibition induces uncontrolled neuronal activity, resulting in paralysis and the subsequent death of fleas and ticks.

PRECAUTIONS- WARNINGS- CONTRAINDICATIONS:

- Use in species other than those authorized is not recommended.
- Do not administer to patients with hypersensitivity to the active ingredient.
- It is recommended for use in dogs from 8 weeks of age and weighing 2 kg or more.
- Use with caution in patients with a history of seizures or neurological abnormalities.

INTERACTIONS:

None have been reported.

ADVERSE REACTIONS:

Vomiting is the most common adverse reaction, although decreased appetite, excessive salivation, lethargy, and diarrhea may also occur. Excessive salivation has been observed in patients that received products intended for topical use orally at high doses.

WITHDRAWAL PERIOD:

Not applicable.

COMMERCIAL PRESENTATIONS:

- Box of 1 tablet – 50 mg
- Box of 1 tablet – 100 mg
- Box of 1 tablet – 200 mg
- Box of 1 tablet – 400 mg